NASDAQ:MEIP
Delisted

Mei Pharma Stock Insider Trading

etoro logo Buy MEIP
*Your capital is at risk
$3.07
+0 (+0%)
At Close: Dec 09, 2025

MEI Pharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 1.54M and sold 60K MEIP shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
100.00
Buy 1.54M shares
Sell 60K shares
80% Buy Activity
Moderate Positive Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
Dec 18, 2023
Buy
Stock Option (Right to Buy)
A-Award
Flynn James P
Director
Director 6 700
Value: $41.5K
Dec 18, 2023
Buy
Stock Option (Right to Buy)
A-Award
Wood Steven D
Director
Director 10 000
Value: $61.9K
Dec 18, 2023
Buy
Stock Option (Right to Buy)
A-Award
Wood Steven D
Director
Director 6 700
Value: $41.5K
Dec 18, 2023
Buy
Stock Option (Right to Buy)
A-Award
Wood Steven D
Director
Director 6 700
Value: $41.5K
Dec 18, 2023
Buy
Stock Option (Right to Buy)
A-Award
Wood Steven D
Director
Director 10 000
Value: $61.9K
Dec 18, 2023
Buy
Stock Option (Right to Buy)
A-Award
Flynn James P
Director
Director 6 700
Value: $41.5K
Dec 18, 2023
Buy
Stock Option (Right to Buy)
A-Award
Flynn James P
Director
Director 10 000
Value: $61.9K
Dec 18, 2023
Buy
Stock Option (Right to Buy)
A-Award
Wood Steven D
Director
Director 10 000
Value: $63.3K
Dec 18, 2023
Buy
Stock Option (Right to Buy)
A-Award
Wood Steven D
Director
Director 6 700
Value: $42.4K
Dec 18, 2023
Buy
Stock Option (Right to Buy)
A-Award
Flynn James P
Director
Director 10 000
Value: $63.3K
Dec 18, 2023
Buy
Stock Options (Right to Buy)
A-Award
Flynn James P
Director
Director 6 700
Value: $42.4K
Dec 18, 2023
Buy
Stock Options (Right to Buy)
A-Award
Flynn James P
Director
Director 6 700
Value: $42.4K
Dec 18, 2023
Buy
Stock Option (Right to Buy)
A-Award
Flynn James P
Director
Director 10 000
Value: $63.3K
Dec 18, 2023
Buy
Stock Option (Right to Buy)
A-Award
Wood Steven D
Director
Director 6 700
Value: $42.4K
Dec 18, 2023
Buy
Stock Option (Right to Buy)
A-Award
Wood Steven D
Director
Director 10 000
Value: $63.3K
Oct 31, 2023
Buy
Common Stock
Wood Steven D
Director
Director 0
Value: $0
Oct 31, 2023
Buy
Common Stock
Wood Steven D
Director
Director 0
Value: $0
Oct 31, 2023
Buy
Common Stock
Wood Steven D
Director
Director 0
Value: $0
Oct 31, 2023
Buy
Common Stock
Wood Steven D
Director
Director 0
Value: $0
Oct 31, 2023
Buy
Common Stock
J-Other
Datoo Taheer
Director 0
Value: $0
Oct 31, 2023
Buy
Common Stock
J-Other
Datoo Taheer
Director 0
Value: $0
Oct 31, 2023
Buy
Common Stock
J-Other
Flynn James P
Insider
Other 0
Value: $0
Oct 31, 2023
Buy
Common Stock
J-Other
Flynn James P
Insider
Other 0
Value: $0
Oct 20, 2023
Buy
Common Stock
X-InTheMoney
Funicular Funds, Lp
10 Percent Owner
10% Owner 120 600
Value: $844.2K
Oct 20, 2023
Sell
Put Option (obligation to buy)
X-InTheMoney
Funicular Funds, Lp
10 Percent Owner
10% Owner 1 206
Value: $8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT MEI PHARMA
MEI Pharma
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cycl...
GOLDEN STAR
Ticker Change Signal Date
NESR
$25.06
0.439% Jun 22
IDYA
$28.98
25.19% Jun 12
PHM
$118.49
14.53% Jun 10
DHI
$146.71
13.50% Jun 10
EAT
$140.46
20.94% Jun 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE